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ABSTRACT: Background. Local and/or regional recurrence and meta-
chronous primary tumor arising in a previously irradiated area are rather
frequent events in patients with head and neck squamous cell carcinoma
(HNSCC). Re-treatment is associated with an increased risk of serious
toxicity and impaired quality of life (QOL) with an uncertain survival
advantage.
Methods. We analyzed the literature on the efficacy and toxicity of pho-
ton/electron-based external beam reirradiation for previously irradiated
patients with HNSCC of non-nasopharyngeal origin. Studies were
grouped according to the radiotherapy technique used for reirradiation.
Patient selection criteria, target volume identification method, tumor
dose, fractionation schedule, systemic therapy administration, and toxic-
ities were reviewed.
Results. In addition to disease-related factors, current comorbidities and
preexisting organ dysfunction must be considered when selecting
patients for reirradiation. As morbidity from re-treatment may be consid-
erable and differ depending on which mode of re-treatment is used, it is
important to give patients information on potential morbidity outcomes
so that an informed choice can be made within a shared decision-
making context. With improved dose distribution and adequate imaging
support, including positron emission tomography-CT, modern radiother-
apy techniques may improve local control and reduce toxicity of
reirradiation. A reirradiation dose of 60 Gy and a volume encompass-
ing the gross tumor with up to a 5-mm margin are recommended. Con-
comitant administration of systemic therapeutics and reirradiation is
likely to be of similar benefit as observed in large randomized studies of
upfront therapy.
Conclusion. Reirradiation, administered either with or without concurrent
systemic therapy, is feasible and tolerable in properly selected patients
with recurrent or a new primary tumor in a previously irradiated area of
the head and neck, offering a meaningful survival (in the range of 10%
to 30% at 2 years). Whenever feasible, salvage surgery is the method of
choice for curative intent; patients at high-risk for local recurrence
should be advised that postoperative reirradiation is expected to increase
locoregional control at the expense of higher toxicity and without survival
advantage compared to salvage surgery without reirradiation. VC 2014
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INTRODUCTION
Initial multimodality treatments for locally advanced
head and neck squamous cell carcinoma (HNSCC) can
be unsuccessful, resulting in persistent or recurrent dis-
ease, and the past and current lifestyle choices of many
patients increase their risk for new primary cancers
even if the initial tumor was cured. Recurrent and sec-
ond primary HNSCC in previously radiated regions
pose a unique challenge to clinicians dealing with this
disease. As multidisciplinary management is common
in head and neck oncology, most of these patients
already have received considerable intensified prior
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treatment consisting of surgery, radiotherapy (RT), and/
or chemotherapy.
In the present study, we reviewed the efficacy and tox-
icity of photon/electron-based external beam reirradiation
as salvage treatment of HNSCC for patients previously
irradiated for HNSCC primary tumors of non-
nasopharyngeal origin. Reports using brachytherapy as
the main reirradiation procedure were not included in the
present analysis.1
MATERIALS AND METHODS
A systematic review of the English-language literature
was conducted using the PubMed database with the fol-
lowing search terms: reirradiation, re-treatment, and head
and neck cancer. The content of publications identified in
the search results was reviewed for possible inclusion,
and references were checked for additional relevant
reports. Only studies fulfilling the following criteria were
included: (1) published as a full article in peer-reviewed
journals; (2) the majority of patients had non-
nasopharyngeal primaries and the prevailing histology
was squamous cell carcinoma; (3) results for different RT
techniques were reported separately; and (4) overall sur-
vival (OS) data was reported or could be estimated from
the Kaplan–Meier plot.
Depending on the RT technique used in a particular
study, salvage treatments were divided into 4 groups: (1)
salvage surgery performed with curative intent in combi-
nation with reirradiation using conventional techniques;
(2) reirradiation for unresectable disease using conven-
tional techniques; (3) reirradiation using intensity modu-
lated radiotherapy (IMRT); and (4) reirradiation using
stereotactic body radiotherapy (SBRT). In addition, the
quantitative aspect and other issues specifically related to
reirradiation (target volume definition, tumor dose, regi-
men, and tolerance of reirradiated tissues) were reviewed
and discussed together with systemic drugs used in con-
junction with reirradiation and criteria for the selection of
patients who are likely to benefit from aggressive
reirradiation programs.
RESULTS
Extent of the problem
By definition, HNSCC is largely a locoregional prob-
lem, with the distribution of most recurrences after pri-
mary, curative-intent RT regimens occurring within the
treatment field. According to the Meta-Analysis of Chem-
otherapy in Head and Neck Cancer (MACH-NC) data
from 50 concomitant chemotherapy-RT trials and 30
induction chemotherapy trials, the rates of local and/or
regional recurrence at 5 years were 50.8% and 47.5% in
the experimental arms, respectively, and 60.1% and
46.5% in the control arms (ie, RT alone) of the trials,
respectively.2 The corresponding rates of distant metasta-
sis were below 20%. Although patients with locoregional
tumor recurrence can be considered salvageable with sur-
gical and/or reirradiation-based therapies, considering the
health status and preferences of patients with recurrence,
morbidity after previous therapies and the extent of the
disease, approximately half or less were amenable to sal-
vage surgery or other curative intent treatment strat-
egies.3–6
Another indication for re-treatment in a previously irra-
diated area of the head and neck is metachronous
HNSCCs. Their appearance relates to a lengthy exposure
of the upper aerodigestive tract mucosa to the immoderate
use of tobacco and alcohol, resulting in a “field cancer-
ization” effect, and genetic predisposition.7,8 Analyzing
the Radiation Therapy Oncology Group (RTOG) registry
with 2066 patients prospectively entered with HNSCC,
Cooper et al9 identified 601 patients without prior/coinci-
dent of another malignant tumor who were treated with
RT alone and were free of disease at 6 months postther-
apy. The estimated risk of developing a second malignant
tumor in these patients at 3, 5, and 8 years (plus 6
months) from the start of RT was 9%, 14%, and 23%,
respectively, and the proportion of new primary tumors
arising in the head and neck was 18%. A study presenting
the University of Florida experience on 1112 patients
with HNSCC treated with curative RT and followed for
at least 2 years was reported by Erkal et al.10 Among
these patients, there were 9% who developed a new
HNSCC at 0.6 to 21.7 years after RT, and the rates of
occurrence of a second primary HNSCC at 5 years by the
site of the initial malignancy were 11%, 12%, and 3% for
patients with carcinoma of the oropharynx, hypopharynx,
and supraglottic larynx, respectively. In the series from
the MD Anderson Cancer Center, 3.4% of 1292 patients
with HNSCC who completed different treatment programs
developed a second HNSCC, corresponding to 36.7% of
all second primary tumors diagnosed in this cohort.8
Re-treatment strategies
Patients who present with a locoregional recurrence or
a second primary HNSCC are frequently heavily pre-
treated with surgery and RT, with or without chemother-
apy, or both. Surgical salvage has proven to be the most
effective curative-intent treatment and is the treatment of
choice for all patients with resectable tumors and suffi-
ciently good health status. According to a meta-analysis
of 32 studies with a total of 1080 patients reported by
Goodwin,11 a survival rate of 39% can be expected at 5
years after salvage surgery. The best chance for cure has
been reported for patients with early-stage recurrent
tumors, whereas those with rT3-classified and rT4-
classified recurrent disease should be considered poor
candidates to undergo salvage surgery.3,11,12 The efficacy
of salvage surgery also correlated with the site of recur-
rent cancer, and the outcome tended to be better in recur-
rent cancer of the larynx as compared to other tumor
sites. However, the impact of the treated site was found
to be less important than recurrence stage.11
The role of chemotherapy as a single therapeutic
modality in such patients is palliative. A phase III clinical
trial has shown that the median survival of patients with
recurrent, unresectable HNSCC can be improved from 7.4
to 10.1 months (hazard ratio [HR], 0.80; p5 .04) with the
addition of cetuximab to platinum/5-fluorouracil (FU)
systemic therapy.13 However, it is known from earlier
randomized trials in recurrent/metastatic HNSCC that,
with platinum-based combination chemotherapy, only
3.6% of patients are still alive after 5 years.14
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In recurrent, unresectable head and neck cancer, deci-
sion analysis models informed by results from systematic
reviews and expert panel-generated utility values showed
that concurrent chemotherapy and reirradiation offers an
improvement in quality of life (QOL)-years of approxi-
mately 5 weeks compared to best supportive care.15
Reirradiation (using conventional techniques) and combinations
with other treatment modalities: a review of effectiveness. In
the era of conventional RT techniques, several retrospec-
tive reports, but only a few prospective studies, have been
published using reirradiation as a salvage modality in
locoregional recurrence and/or second primary HNSCC.
There have been only 2 prospective phase III studies
exploring the efficacy of conventional reirradiation, and
one of them was underpowered because of slow accrual
resulting in premature closure.
Reirradiation after salvage surgery. In 2008, the Groupe
d’Etude des Tumeurs de la Te^te Ed du Cou and Groupe
d’Oncologie Radiotherapie Te^te et Cou (GORTEC) groups
reported on a phase III randomized trial of postoperative
reirradiation combined with chemotherapy compared with
salvage surgery alone.16 Between 1999 and 2005, a total of
130 patients from 16 French and Belgian centers were
randomized to the trial arms. Surgical resection encom-
passed a lymph node dissection in 84% of patients,
although two-thirds had cN0 disease. Histopathological
examination of the resected specimens revealed positive/
close margins, extracapsular rupture, or >1 invaded nodes
in 49% of the patients. In the experimental arm, patients
were to receive 6 cycles of 5 3 2 Gy/fraction (fx)
reirradiation, concomitantly with hydroxyurea/5FU, with
a 9-day rest period between cycles. The tumor bed with a
1- to 2-cm margin and the first adjacent metastasis-free
nodal area were irradiated. Significant improvements in
locoregional control (LRC; HR, 4.51; p < .0001) and
disease-free survival (DFS; HR, 1.68; p5 .01) were
observed in the reirradiation arm, but OS (45% at 2 years
in the reirradiation arm) did not differ between the 2 arms
because of more treatment-related deaths, distant metasta-
ses, and second primary tumors among the reirradiated
patients. An increase in serious (grade 3 or 4) late toxicities
was associated with adjuvant therapy (39% vs 10% at 2
years; p5 .06), and 5 treatment-related deaths were
recorded in this group.
Several smaller prospective or retrospective series have
been reported in the literature, and the main characteris-
tics and results from these reports are presented in Table
1.16–25 Conclusions drawn from these studies might
include the following: (1) only patients with high-risk fea-
tures found at histopathological examination of the
resected specimen should be considered for postoperative
reirradiation (eg, close or involved surgical margins and
extracapsular tumor extension); (2) grade 3 or 4 late tox-
icities occur in greater than a third of the patients; (3) up
to 8% of patients will die because of causes related to re-
treatment; (4) OS rates in the range of 40% to 50% at 2
years are achievable (in a selected population of fit
patients with smaller tumor volumes than in those not
amenable to salvage surgery); and (5) compared to sal-
vage surgery alone, adjuvant reirradiation (with or with-
out concomitant chemotherapy) improves LRC and DFS
but has no effect on OS. It is not clear whether the addi-
tion of concurrent chemotherapy to reirradiation improves
treatment efficacy.
The morbidity and mortality associated with adjuvant
reirradiation cannot be understated. Some have suggested
that the introduction of vascularized tissue in the form of
a muscle flap may help to protect the vascular structures
and the overlying skin from radiation injury. Suh et al24
retrospectively evaluated 12 patients who received micro-
vascular free flap reconstruction for recurrent or second
primary head and neck cancer in a previously irradiated
field. All free flaps were inset directly into the field of
previous radiation and were exposed to reirradiation. The
authors compared their results with the published compli-
cation rate and they found that microvascular free flaps
allow for maximal resection and reliable reconstruction of
previously irradiated cancers before high-dose reirradia-
tion and may reduce the incidence of severe late compli-
cations and treatment-related mortality. In those patients
who are undergoing salvage surgery with the intent on
reirradiation, the introduction of vascularized tissue may
reduce the rate of skin sloughing, spontaneous fistula, and
great vessel rupture.
Reirradiation for unresectable disease. The only trial with
randomized design was conducted by the French Head
and Neck Oncology Radiotherapy Group (GORTEC 98-
03) during 1999 to 2005 and was closed prematurely.26
Only 57 patients (of a planned 160 patients), unsuitable
for any curative salvage therapy, were randomized
between weekly single agent methotrexate (until disease
progression or toxicity, 27 patients) or 6 cycles of
reirradiation (5 3 2 Gy/fx/cycle) and concurrent hydrox-
yurea/5FU (30 patients), with a 9-day intercycle rest
period. The irradiated volume encompassed the gross
tumor volume (GTV) with 2-cm margin and the first
adjacent nodal station. With more rT3-4 tumors in the
reirradiation arm (88% vs 60%), 4 patients from this
group experienced a complete response (but none in the
methotrexate arm), although no differences in OS was
found between the 2 approaches (1-year survival, 22% vs
23%; p5 .6). The reirradiation arm proved to be more
toxic compared to the methotrexate arm with regard to
treatment-related deaths (3 vs 1) and grade 3/4 late toxic-
ities (11 vs 5).
In 2004, the RTOG launched a phase III randomized
trial (RTOG 04-21) comparing concomitant chemotherapy
and reirradiation (the same regimen as in the RTOG
9911, see below) and 3 cisplatin-based standard chemo-
therapy regimens. As in the case of the GORTEC 98-03
trial, it was closed prematurely because of poor accrual,
and results have not been reported.
However, the RTOG designed and successfully con-
ducted 2 multi-institutional prospective phase II trials. In
the RTOG 9610 trial (1996–1999), a total of 86 patients
were recruited and treated with 4 weekly cycles of chem-
otherapy and reirradiation (1.5 Gy/fx b.i.d., concurrently
with hydroxyurea/5FU, days 1–5), separated by 1 week of
rest.27 Only the gross disease was irradiated with a mar-
gin of 2 cm. Of 79 analyzable patients, all 4 chemother-
apy cycles and >54.6 Gy were received by 73.4% and
77.2% patients, respectively. In the acute phase of the
protocol, there were 6 treatment-related deaths (7.6%);
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69.6% of patients had a feeding tube at the last follow-
up, and the estimated cumulative incidence of late grade
3/4 toxicities at 2 and 5 years was 9.4%. Death was
related to the index cancer in 72.7% of the patients, and
OS was 15.2% at 2 years. The second study (RTOG
9911) was conducted during 2000 to 2003 and included
105 patients who were treated according to the same
reirradiation protocol (IMRT was allowed and used at the
discretion of the investigator) but with a different chemo-
therapy regimen (cisplatin/paclitaxel, concurrently with
reirradiation, days 1–5) and granulocyte colony-
stimulating factor support (days 6–13, every other
week).28 All 4 chemotherapy cycles were completed in
74% of 99 analyzable patients, and 76% of patients
received >52.5 Gy. The incidence of grade 3/4 late
adverse effects was 33.8%, and the incidence of
treatment-related deaths was 8% (early 5, late 3). At 2
years, progression-free survival and OS were 15.8% and
25.9%, respectively, with 71% of deaths recognized as
cancer-related. Comparing the outcome results from
RTOG 9610 and RTOG 9911, the OS rate seems superior
in the latter trial (p5 .0444).
The studies using reirradiation in patients with unre-
sectable tumors are listed in Table 2.17,23,25–51 The review
of the reported results shows that at 2 years, one quarter
to one third of the patients will be free of locoregional
tumor; OS rates in the 10% to 30% range can be expected
at 2 years of follow-up, although long-term survivors are
rare. Late toxicities of grade 3/4 severity may occur in up
to 40% of reirradiated patients, and nearly 10% of
patients will have treatment-related deaths. Obviously, the
outcomes differ considerably across these studies and
depend primarily on the selection criteria for re-treatment
and intensity of the applied therapies. Moreover, there are
still questions regarding the most effective reirradiation
regimen (split-course vs continuous-course; once-
daily fractionation vs hyperfractionation) and on the
added value of concurrent chemotherapy that remain
unanswered. To date, no randomized comparison of
reirradiation treatment schemes has been conducted, and
the wide diversity in patient populations and in tumor-
related and treatment-related parameters across the
reported studies prevents any meaningful conclusions.
There are several reasons why the treatment results in
the reirradiation series dealing with unresectable disease
are inferior when compared to the adjuvant (postopera-
tive) reirradiation series. First, patients referred for sal-
vage surgery have, by definition, operable, lower-volume
tumors, compared with those referred for reirradiation,
implying, per se, a higher probability for cure in such
cases. Furthermore, in surgical candidates, the processes
of tissue scarring, initiated during the previous course of
RT, are expected to be less prominent and, consequently,
involved tissues are likely less hypoxic. After salvage sur-
gery, tumor burden is considerably reduced, and less
compromised vasculature and better oxygenation in the
treated area make residual tumor cells more sensitive to
subsequent RT and better exposed to systemic drugs than
is probably the case in patients not amenable for salvage
surgery. Last, only patients with good performance status
are suitable for general anesthesia and a major surgical
procedure, which is a prerequisite for a successful
completion of the planned therapy and subsequent
rehabilitation.
How to irradiate
Experiences with re-treatment of patients with head and
neck cancer gained during the last decades provide a solid
ground for refinement of the existing reirradiation strat-
egies. Moreover, given the enormous progress in RT tech-
nology and targeted drug development, several exciting
novel paradigms bring new optimism to these patients
with traditionally poor prognosis.
Reirradiation volumes. The main challenge in a
reirradiation setting is the extent of the clinical target vol-
ume (CTV), expanding around the recurrent primary
tumor or regional lymph nodes, and whether to electively
irradiate the neighboring noninvolved nodal area(s). In
this respect, several observations should be taken into
account. First, after performing contrast-enhanced CT of
the neck in the post-RT setting, the negative predictive
value for regional metastases is >94%.52 Second, differ-
ences in the pattern of metastases (the incidence and/or
geographic distribution of metastases) can be expected
after previous RT. Changes in nodal size and the caliber
of lymphatic vessels have been observed in the irradiated
lymphatic tissue, with marked hyalinization and fibrotic
changes found in lymph nodes irradiated with doses of
>40 Gy.53–55 Also, lymphoscintigraphy performed as part
of the sentinel node procedure in early oral cancer
showed an unexpected lymph drainage pattern in 67% of
the patients with a previously treated neck.56 Third, high
rates of local failures and systemic metastases reported in
patients after local and/or regional salvage treatment
markedly reduce the potential therapeutic gain that would
be expected from elective RT.57 Locoregional recurrence
and second primary tumors have been identified as high-
risk factors for the development of distant metastases.58
Considering only recent reirradiation series with a more
consistent utilization of contemporary imaging for target
determination and computer-assisted three-dimensional
(3D) RT planning,57,59–69 it seems that, at the site of
recurrence, the reirradiation CTV should include the
GTV/tumor bed with no or only a narrow margin (0.5
cm) of the normal-appearing surrounding tissue. The mar-
gin is intended to cover potential microscopic tumor
extensions and/or compensate for geographic uncertainties
originating from an imperfect visualization of the tumor/
normal-tissue border, as well as differences in the appear-
ance of the GTV resulting from the implementation of
various imaging modalities.70
The need for any “safety” margin around GTV was ques-
tioned by Popovtzer et al.57 They expanded GTV by 0.5 cm
to form a planning target volume (PTV): 45 to 47 (96%) of
local failures in their series occurred within the high-dose
reirradiation volume. Moreover, using SBRT, Wang et al71
used no margin at all around the visually delineated GTV
(GTV5CTV5PTV). In the non-positron emission
tomography-CT (non-PET-CT) planning group, 25 of 44
patients (57%) had a local recurrence: 11 of 25 recurrences
(36%) occurred “in field” (20% of the recurrent tumor
inside the GTV), whereas 14 of 25 recurrences (64%) were
declared as marginal (<20% inside the GTV, but with the
STROJAN ET AL.
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closest edge within 1 cm of the GTV). In the PET-CT plan-
ning group (45 patients with 16 local recurrences), there
were only 6 of 16 marginal failures (38%). After retrospec-
tively adding margins of 1 to 5 mm to the GTVs, a median
coverage of recurrence volumes, as measured by the GTV-
recurrence volume overlap, increased from 11.7% (GTV
10 mm) to 48.2% (GTV 15 mm) in non-PET-CT patients
and from 45% to 93.6% in PET-CT–planned patients. The
authors concluded that margins of up to 5 mm around the
GTV may effectively reduce failures but could possibly
increase toxicity. The similarity of GTV size and disparity
of outcome between the 2 types of planning suggests that
PET-CT planning may alter GTV location rather than vol-
ume. With PET-CT planning, near-miss failures can be
effectively reduced with a smaller increase in GTV size.
With regard to elective reirradiation of the regional
lymphatics, 3 clinical scenarios must be considered. First,
in patients with isolated local recurrence and clinically
and radiographically N0 necks who were originally
treated with elective RT to cN0 necks, the risk of occult
neck disease is generally low, usually not justifying elec-
tive treatment to the neck. Dagan et al72 reported on 57
such patients who underwent salvage surgery of recurrent
primary with or without neck dissection. Occult metasta-
ses were found in 4 of 46 dissected specimens (9%; in 4
of 40 patients; 10%), and only 1 of the observed patients
had neck recurrence. None of these patients had an iso-
lated neck recurrence. By adding neck dissection, no
improvement in LRC, cause-specific survival, or OS was
found, whereas the likelihood of adverse events was
increased. Summarizing the results from 6 recent litera-
ture series dealing with patients surgically salvaged for
isolated locally recurrent HNSCC72–77 after (chemo)-RT
for initially staged cN0 HNSCC, the rate of pathologi-
cally involved nodes was 10% among a total of 274 pat-
ents. A comparably low rate of occult nodal metastasis
(8%) was found in 13 patients diagnosed with a second
node-negative primary HNSCC who had already received
elective neck RT.78 In patients with recurrent supraglot-
tic/hypopharyngeal tumors or rT3-4 tumors, however, the
risk of occult metastases in the neck lymphatics seems
higher, and these patients may benefit from elective
(re)treatment of the neck.73,75,79
The second scenario includes patients with an isolated
local recurrence who were initially treated for node-
positive disease. In this group, elective treatment of
regional lymphatics might be indicated. Solares et al80
reported on 69 patients who underwent 96 selective neck
dissections and found histologically positive nodes in
25% of the patients (23% of the operated hemi-necks).
There were no recurrences in salvaged necks when the
primary site was controlled, and the pattern of lymphatic
spread was found unaffected by previous RT. In the
recent series of Amit et al,79 elective dissection revealed
occult nodal metastases in 4 of 8 patients (50%) and 2 of
26 patients (8%) who received RT to the neck at initial
treatment for N1 and N0 disease, respectively. In the
group previously irradiated for early-stage (T1–2N0) glot-
tic (12 cases) or supraglottic (2 cases) primaries but hav-
ing no elective neck RT, the rate of occult metastases
was 14% (2 of 17 neck specimens; 12%), whereas the
risk of metastases in the contralateral neck was 0% (0 of
9). Recently, Lee et al81 also found a significant advant-
age for elective neck dissection during salvage surgery in
node-positive patients at initial treatment and recurrent
cases that developed within 1 year.
The third scenario consisted of patients with isolated
regional recurrence. In line with the surgical experiences
and differences related to the use of previous neck RT,
the CTV in adjuvant reirradiation should include only the
involved nodal levels, whereas for unresectable neck
tumor, the CTV should encompass the GTV with a mar-
gin, adapted to a geographic distribution of high-dose
areas created during previous RT to the neck.82
Radiotherapy regimen and normal tissue tolerance to reirradia-
tion. No objective comparison of various reirradiation
regimens has been conducted to date. Experiences col-
lected from irradiation of RT-naive patients with HNSCC
suggest hyperfractionated regimens with proven capacity
for sparing late-reacting normal tissues in the vicinity of
the target to be the most effective.83 A rather high
fraction dose of 1.5 Gy delivered twice daily in “1-week-
on/1-week-off” or similar fashion was tested by the
RTOG and in some others studies.21,23,27,28,36,37,43,47 No
apparent advantage of these prolonged regimens was seen
with regard to treatment efficacy or toxicity compared
to similar split-course regimens using 1 daily
fraction16,20,23,35–38,46,48 or continuous course regimens
with either hyperfractionation or conventional fractiona-
tion of 1.8 to 2 Gy/day.18,22,29–34,36,39–42,44,45,49–51
In the majority of reirradiation studies, the reported
profile of acute toxicity remains within the limits of those
observed during the initial course of RT or it was less
intensive, probably because of smaller target volumes
used in reirradiated patients. Specifically, hematologic
toxicity depends primarily upon the intensity of systemic
component of the re-treatment regimen and is usually not
affected by prior therapy. Conversely, this is not the case
with late radiation-induced morbidity. In a cohort of 103
patients treated between 1998 and 2008, late toxicities of
grade 3 occurred in 47.5%84 and, in another study using
different RT techniques, they were found more frequent
in patients treated with 3D-conformal RT than in patients
treated with IMRT (44% vs 7%; p < .05).69 Even though
there is usually a window, albeit narrow, to burden pre-
irradiated late-reacting tissues with an additional dose,
including the spinal cord as the most critical among these
structures, the need for reducing the extra dose as much
as possible is obvious.
Ang et al85 demonstrated a significant capacity of the
spinal cord to recover from occult radiation injury. Mod-
eling clinical data from reirradiation experiments per-
formed on monkeys previously irradiated to 44 Gy in a
2.2-Gy per daily fraction, recovery estimates of 76%,
85%, and 101% of the initial dose, after 1, 2, and 3 years,
respectively, at the 5% incidence level for myoparesis,
were done. Recently, Kirkpatrick et al86 summarized the
existing knowledge on this issue and concluded that a
partial repair of subclinical damage in the cord produced
by conventionally fractionated RT of the full cord cross-
section becomes evident about 6 months post-RT (ie,
reirradiation at 2 Gy/day: increase in cord tolerance of at
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least 25%) and increases over the next 2 years. For partial
cord RT using SBRT, a maximum cord dose of 13 Gy/1
fx or 20 Gy/3 fx seems associated with a <1% risk of
injury. In routine practice, Sulman et al63 assumed, using
this background data, a 50% dose tolerance recovery of
central nervous system structures, if the posttreatment
interval is 12 months. Also, Nieder et al87 suggested
that the spinal cord might tolerate significant reirradiation
doses (eg, 25 Gy in 30 fractions after previous exposure
of 45 Gy in 35 fractions). Several studies reported on the
methods for an accurate assessment of the delivered dose
on different spinal cord sections and planning techniques
to spare doses to the spinal cord and brainstem, which
could be of considerable importance in a reirradiation
setting.88,89
A pooled analysis of published data on carotid blowout,
another dreaded complication of reirradiation, determined
a rate of 2.6% at a median of 7.5 months post-
reirradiation; 76% of events were fatal.90 No impact of
previous salvage surgery or administration of concurrent
chemotherapy was established. A lower rate of carotid
blowout was found among patients treated in a continuous
course with conventional fractionation or hyperfractiona-
tion compared to accelerated hyperfractionation regimens
(1.3% vs 4.5%; p5 .002), although a heterogeneous
patient population and treatment parameters preclude
definitive conclusions about the impact of fractionation.
The estimated incidences of other late radiation-induced
toxicities are less systematic and accurate. Swallowing
impairment seems to be the most common toxicity,
reported in up to 50% or more of treated
patients.27,48,67,91 However, dysphagia is still less frequent
than expected, particularly when the baseline functional
status resulting from the first RT course is taken into
account.27,44,48 Because of the same reason, sparing of
parotid glands during reirradiation planning is of minor
importance. The rates of mandibular osteoradionecrosis
reported in larger reirradiation series using predominantly
conventional RT techniques were up to 10%,36,84,91 and
did not correlate with any of the RT/reirradiation parame-
ters.36 Because of more precise planning and targeting,
reirradiation with modern RT techniques (IMRT, SBRT)
resulted in a significantly reduced rate of mandibular
necrosis, ranging from 0% to 7% (median 0%).57,59–69,92–
101 Obviously, options offered with reconstructive surgery
as a necrosis-rescuing procedure or preventative swallow-
ing exercise programs cannot outweigh the importance of
precise RT planning and dose delivery.102 Besides the
mandibular bone, other tissues, like the laryngeal carti-
lages and brain, are also sensitive to radiation. Conse-
quently, the localization of the tumor influences the type
of radiation-induced toxicity.
Tumor regrowth is thought to result from repopulation
of radioresistant clonogens that survive the first course of
RT, which are likely to be more difficult to control with
a repeated course of RT. From this perspective, high RT
doses seem mandatory, although, in a reirradiation
scenario, one must consider the tradeoff for the efficacy
and morbidity of high-dose RT. A dose-effect relatio-
nship was established in several reirradiation
studies.17,23,25,29,30,33–36,38,40,47–49,51,59,60,63,84,91–93 In dif-
ferent studies, the cut-point dose suggesting an improved
outcome is usually set at around 60 Gy. By increasing the
dose above this level, extreme caution is warranted, as
the aim to cure does not always justify excessive morbid-
ity and deterioration in the patient’s QOL. Thus, when
deciding on the reirradiation dose, one must take into
account the volume of the tissue to be reirradiated (GTV
with margin, eventually neighboring lymph node
stations), the level of precision of the RT technique
used, and the latency period from the first RT course.
There was a strong relationship established between
treatment-related morbidity and reirradiation vol-
ume,36,39,40,57,64,84,93 RT technique (see below) and
RT-reirradiation time interval.27–30,34,37,38,43,64,84,85,91,94
New irradiation techniques. Capability to deliver nonuni-
form photon fluency from any given position to the treat-
ment beam allows a more precise isodose shaping
(according to the 3D shape of the target), whereas the
increased implementation of modern imaging and stereo-
tactic principle in RT practice resulted in improved dis-
ease targeting. Both modulation of beam intensity and
image guidance were widely adopted in RT practice
because of their potential to significantly change the tox-
icity profile and/or treatment efficacy compared with con-
ventional RT techniques.102–104
Reports on the use of IMRT and SBRT are presented
in Tables 3 and 4.57,59–69,92–101 In general, the numbers of
patients treated in individual series are low and a wide
heterogeneity can be observed with regard to RT details
and implementation of salvage surgery and/or systemic
therapy across these studies. Compared to conventional
techniques, no obvious survival advantage can be
observed with IMRT or SBRT. However, improvement in
local tumor control can be seen, despite the fact that the
treated volumes seem smaller when new RT techniques
are used. No conclusions can be drawn with regard to
toxicity and treatment-related deaths, presumably because
of a less systematic collection of pertinent data in older
series.
Lee et al60 retrospectively evaluated the efficacy and
toxicity data of 105 patients who underwent reirradiation
with curative intent between 1996 and 2005 with either
conventional RT techniques (31 patients) or IMRT (74
patients). The IMRT approach yielded a significantly bet-
ter locoregional recurrence-free survival over non-IMRT
techniques at 2 years (52% vs 20%; p < .001) and was
also recognized as an independent prognosticator in the
multivariate analysis (HR, 0.37). For OS, the advantage
of the IMRT technique was only observed by univariate
analysis, implying that an improvement in LRC did not
transfer to improve the OS. No separate data on toxicity
was presented for the 2 treatment groups. For locally
recurrent nasopharyngeal carcinoma, 3D-conformal RT
(27 patients) and robotic SBRT (24 patients) were com-
pared by Ozyigit et al.105 No apparent difference in tumor
dose, volume, and time interval between the first RT and
reirradiation was found between the groups; in 3D-
conformal RT patients, larger margins were used
(PTV5GTV 15–10 mm vs PTV5GTV), and the cumu-
lative nasopharyngeal dose was lower (128.2 Gy vs 132.6
Gy; p5 .1). At 2 years, local control rates were similar in
the 2 groups (80% vs 82%), with no significant difference
in cancer-specific survival (47% vs 64%). However,
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serious late complications were more frequent with 3D-
conformal RT (48% vs 21%; p5 .04), but the incidence
of fatal complications was comparable (14.8% vs 12.5%),
and no correlation was found between the cumulative
nasopharyngeal dose and the rate of serious late adverse
events.
Combinations with systemic agents. Whether the addition of
systemic agents to RT improves the effectiveness of
reirradiation is not known. There have been no head-to-
head comparisons of reirradiation versus combined modal-
ity therapy, and the results of selective studies implement-
ing reirradiation alone compete favorably with those of
chemotherapy reirradiation series. For example, in a defini-
tive and postoperative setting, excellent LRC and OS were
reported using only a well-defined RT protocol without any
chemotherapy.22,44 The explanation may lay in the refine-
ment of RT procedures that can counterbalance the addition
of systemic drugs, although a reduced effectiveness of sys-
temic agents in a reirradiation setting could not be
excluded. On the other hand, presented results are based on
small and mainly retrospective studies: taking into account
the fact that in large randomized studies of upfront RT vs
chemotherapy-RT the survival benefit is about 6%, there is
simply no chance to detect a potential benefit of concomi-
tant chemotherapy in these retrospective series.2 One may
hypothesize that the benefit of concurrent chemotherapy,
and also cetuximab, in a reirradiation setting is likely to be
similar to their respective benefits in large randomized
studies of upfront therapy.
Considering the report from the MACH-NC, concomi-
tant administration of systemic drugs with reirradiation
would be expected to increase treatment intensity and
result in an improved outcome compared to reirradiation
alone.2 Few studies reported on an improved outcome
with an increase in the intensity of the chemotherapy
component of re-treatment regimens.28,47,48 In this
respect, an intriguing finding was reported by Choe
et al,91 who analyzed the treatment results and survival of
166 previously irradiated patients with nonmetastatic
HNSCC from 9 consecutive phase I and II protocols on
concurrent chemotherapy and reirradiation. Half of the
cohort (48.8%) underwent salvage surgery or debulking
before reirradiation, with a median dose of 66 Gy. After
dividing the patients with respect to previous use of
chemotherapy, significantly better OS (at 2 years: 28.4%
vs 10.8%; p5 .0043) and DFS (p5 .0008) rates were
recorded in chemotherapy naive patients. A similar obser-
vation was reported by Nagar et al.42 Patients who had
initial RT did significantly better (DFS, p5 .01; OS,
p5 .008) compared with those who were initially treated
by concomitant chemo-RT. One can hypothesize that pre-
vious intensive chemotherapy-RT regimens resulted in a
more pronounced proliferation of fibrous tissue in the
treated area, and when ineffective, it is likely that recur-
rence consisted of surviving highly RT-resistant tumor
clonogens. In poorly vascularized, fibrotic regions, drug
delivery is compromised and RT-resistant hypoxic areas
are more extensive. Consequently, subsequent treatment
may not be as effective as expected.
Several different chemotherapy regimens have been uti-
lized concurrently with reirradiation, most frequentlyTA
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platinum-based and those consisting of 5FU-hydroxyurea
platform invented and extensively tested at the University
of Chicago.23,91 However, no comparison of their efficacy
is possible, mainly because of the retrospective nature of
the reports and heterogeneity of different study parameters.
Furthermore, the toxicity reporting seems inconsistent in
many of these studies, not allowing any reliable assessment
of the tolerance and safety of the tested regimens. Several
combinations of reirradiation and other/new drugs were
tested in phase I settings: bendamustine, an alkylating
agent,106 the hypoxia-targeting agent tirapazamine,45 the
proteasome inhibitor bortezomib,107 the epidermal growth
factor receptor inhibitor erlotinib, alone or in combination
with cyclooxygenase-2 inhibitor celecoxib,108,109 antivas-
cular endothelial growth factor agent bevacizumab,46 and
the paclitaxel-cisplatin combination.110 No apparent
advantage in the efficacy or toxicity profile was observed
in these studies compared to more frequently used chemo-
therapy and reirradiation combinations.
More information is available on reirradiation with
cetuximab, which proved effective in combination with
RT, with acceptable toxicity in therapy-naive patients.111
Moreover, the toxicity profile differed significantly from
that associated with the platinum-based and other chemo-
therapy regimens usually used in patients with HNSCC.
In addition to small retrospective and pilot-study
reports,25,49,50,66,99 there are 2 larger series on the use of
cetuximab and reirradiation.97,112 Heron et al97 used
standard-dose cetuximab concurrently with SBRT (5 3 8
Gy delivered every other day) in 35 patients with recur-
rent HNSCC, who were matched with 35 patients re-
treated with SBRT alone. Patients were matched by age,
sex, performance status, year of treatment, and prior ther-
apy, including radiation dose, interval to recurrence, as
well as recurrent disease characteristics (site, size, and
presence of systemic metastases). At 2 years, the local
control rates were 33.6% for the SBRT-alone group and
49.2% for the cetuximab-SBRT group (HR for local pro-
gression, 0.37; p5 .009), respectively, with 2-year OS
rates of 21.1% and 53.3% (HR for death, 0.59; p5 .031).
A survival advantage was also observed in patients who
received cetuximab during the first course of RT and
were re-treated with cetuximab-SBRT combination. On
multivariate analysis, performance status, nasopharynx
primary, SBRT dose, and cetuximab predicted for
improved survival. There were no grade 4 acute toxic-
ities, no difference in the acute or late toxicity profile
between the 2 groups, and the incidence of grade 3 late
adverse effects were 3% and 6%, respectively.
In another report, Vargo et al112 compared the patient-
reported QOL after SBRT with (51 patients) or without (57
patients) concurrent cetuximab, using the University of
Washington Quality-of-Life Revised Questionnaire. SBRT
consisted of 40 to 50 Gy in 5 fractions, and cetuximab was
administered in standard doses; 24% of patients had sali-
vary gland/paranasal recurrences, mostly of nonsquamous
histology. Overall and health-related patient-reported QOL
and select domains commonly affected by reirradiation (ie,
swallowing, speech, and saliva) progressively showed sig-
nificant improvements to baseline. The addition of cetuxi-
mab to SBRT had no influence on the observed
improvements in QOL. However, the baseline overall QOL
was a significant predictor of OS, with patients denoting
the overall QOL as “poor” or “very poor” (corresponding
to an assigned value of 20) showing statistically inferior
OS at 1 year (23%) compared to patients reporting “fair”
(value >20) baseline QOL (1 year, 48%; p5 .014).
Outside of a clinical trial, cetuximab should be admin-
istered as a single agent during reirradiation. Given the
individual radiosensitizing effects of cetuximab and cyto-
toxic chemotherapies, as well as the potency of cetuximab
administered with platinum-based chemotherapy in incur-
able settings, combining the 2 approaches (cetuximab
plus cisplatin) with RT initially seemed intuitive and
promising. However, the RTOG 0522 phase III trial in
previously untreated patients failed to demonstrate
improved outcomes of the cisplatin/cetuximab combina-
tion over cisplatin alone, suggesting no further enhance-
ment effect above that reached with cisplatin, but yet
leading to more toxicity.113
When to irradiate
Appropriate patient selection is crucial when deciding
on reirradiation to avoid unnecessary morbidity in those
with a short life expectancy. Several risk factors for OS
and adverse events were identified in different studies,
which were recently extensively elaborated by Yamazaki
et al.114 However, low patient numbers, selection bias,
inconsistency in reporting on treatment details and toxic-
ity, and inadequate follow-up make the findings from
these studies questionable.
In 2011, Choe et al91 reviewed their experience with
166 patients with recurrent and second primary HNSCC,
representing the largest reirradiation cohort analyzed so
far, with a median follow-up of 53 months. For OS,
salvage surgery (before reirradiation, HR5 0.52;
p5 .0006), previous chemo-RT (HR, 1.83; p5 .0043),
RT dose 60 Gy (HR, 0.35; p < .0001), and the time
interval from previous RT of 36 months (HR, 0.64;
p5 .0259) were significant independent prognostic varia-
bles. After stratifying the patients according to the num-
ber of prognostic factors present, the OS differed
significantly among the risk groups (p < .0001) with the
rate of 30% at 5 years (estimated from the Kaplan–Meier
plot) in the most favorable risk group (0–1 adverse prog-
nostic factors). All those with 3 to 4 unfavorable risk fac-
tors had died before that time. Patient-related factors had
no influence on the survival in this cohort, most probably
because 80% of the patients were Eastern Cooperative
Oncology Group performance status 0 to 1.
A detailed analysis of the potential prognostic factors
for survival, including comorbidity and preexisting organ
dysfunction, was conducted by Tanvetyanon et al84 on a
group of 103 patients with HNSCC treated with
reirradiation during 1998 to 2008. Comorbidity was
assessed by Charlson index and Adult Comorbidity
Evaluation-27 (ACE-27) grading, whereas organ dysfunc-
tion was defined as feeding tube dependency, functioning
tracheostomy, or soft-tissue defect. On multivariate analy-
sis, in addition to disease-related variables (interval since
last RT, rT-classification, tumor bulk after salvage sur-
gery) and treatment-related variables (reirradiation dose),
organ dysfunction and comorbidity (measured either by
Charlson index or ACE-27 comorbidity grading) also
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exhibited the ability to independently predict survival. If
both comorbidity and organ dysfunction were present, no
long-term survivors were observed (median survival 5.5
months vs 59.6 months in patients with neither of the 2
predictors). Using significant prognostic factors, a nomo-
gram was created to predict the probability of death
within 24 months after reirradiation, taking into account
their contribution to the accuracy of prediction. A good
agreement between the predicted and the observed out-
comes was found with this nomogram (concordance index
0.75), showing a negligible chance of survival at 2 years
after reirradiation for most patients with organ dysfunc-
tion and comorbidity and those who did not have an iso-
lated nodal recurrence. The nomogram has already been
successfully tested by entering data of 28 patients
reported by Shikama et al.101
CONCLUSIONS
The following principles and recommendations based on
prospective and retrospective data analyses should be con-
sidered when planning a treatment strategy for patients
with locoregional recurrence or new primary cancer in a
previously irradiated area (Figure 1). First, proper selection
of patients for reirradiation is crucial. Only those with no or
insignificant comorbidity and toxicity of previous RT
should be considered candidates for re-treatment. If possi-
ble, the functional status of the patient should be assessed
by using standardized measures (ie, the Charlson comor-
bidity index or ACE-27 grading). Other predictors that
should be taken into account are presence of isolated neck
recurrence, tumor bulk, and the time interval from previous
RT, preferably in the context of the published nomogram.84
Second, salvage surgery offers the best chance for cure and
should be performed whenever possible. Patients at high
risk for local recurrence after surgery (eg, positive margins,
extracapsular tumor spread) should be advised that adju-
vant reirradiation is expected to increase LRC at the
expense of higher toxicity and without survival advantage
as compared to no postoperative reirradiation.15 Thrid, new
RT techniques are recommended for patients undergoing
reirradiation. Although there was no significant effect of
IMRT or SBRT on the OS, improved dose distribution with
high isodose conformity and a steep dose gradient at the
target’s margin limits injury to the neighboring tissues and
may improve RT outcomes in terms of local control and
toxicity. Fourth, significant repair of subclinical damage
produced by previous RT can occur in the spinal cord. For
reirradiation of the full cord cross-section at 2 Gy per day,
at least 25% increase in cord tolerance 6 months after prior
conventionally fractionated RT can be considered86 or 50%
dose tolerance recovery if the posttreatment interval is 12
months.63 Fifth, a radiation dose in the range of 60 Gy is
recommended, delivered by using conventional fractiona-
tion (1.8–2 Gy/fx), hyperfractionation, or hypofractionation
(in case of SBRT). With adequate imaging support, pref-
erably implementing PET-CT for target volume determina-
tion, GTV with a margin of up to 5 mm to create CTV
should be irradiated, with no intention to electively treat
the adjacent regions in a majority of patients. Sixth, the
benefit of concurrent chemotherapy (or cetuximab) and
reirradiation is expected to be similar to their respective
benefits observed in large randomized studies of upfront
therapy. Seventh, for patients with poor prognostic factors
who are not candidates for surgery or aggressive
reirradiation with or without concomitant systemic therapy,
palliative systemic therapy and best supportive care remain
appropriate options. Eighth, when available, all patients
should be considered for participation in clinical trials. At
the moment, the key knowledge gaps that should be
addressed in future multi-institutional reirradiation clinical
trials or comparative effectiveness research seem to be the
refinement of selection criteria for aggressive reirradiation
and comparison of different RT techniques (IMRT vs
SBRT) and concomitant systemic therapies.
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